Использование пероральных гипогликемических препаратов при метаболически ассоциированной жировой болезни печени

Метаболически ассоциированная жировая болезнь печени (МАЖБП), ранее называемая неалкогольной жировой болезнью печени (НАЖБП), стала наиболее распространенной причиной заболеваний печени во всем мире. МАЖБП является индивидуальным фактором риска сердечно-сосудистых заболеваний и связанной с ними смертности. Несмотря на распространенность, МАЖБП часто недооценивается и не получает должного внимания во время клинических визитов. МАЖБП является печеночным проявлением метаболического синдрома и поражает около 55% людей, живущих с сахарным диабетом. Новое определение подчеркивает двунаправленные связи и повышает осведомленность в поиске жировой болезни печени среди пациентов с сахарным диабетом и сердечно-сосудистыми заболеваниями или сердечно-сосудистыми факторами риска, а также в поиске этих заболеваний среди пациентов с МАЖБП. Дисфункция печени вносит значительный вклад в развитие сахарного диабета. Хотя эти механизмы не полностью изучены, накопление жира в печени приводит к изменениям в энергетическом обмене и воспалительных сигналах, которые способствуют резистентности к инсулину. Более того, хроническая гиперинсулинемия, наблюдаемая у пациентов с сахарным диабетом, также приводит к накоплению жира в печени. Пациентам с сахарным диабетом могут быть полезны лекарственные средства, которые потенциально оказывают положительное влияние на МАЖБП и заболевания печени. В статье представлены возможности использования гипогликемических лекарственных препаратов при МАЖБП и их влияние на содержание жира в печени, печеночные ферменты, используемые в качестве маркеров стеатоза, и индексы воспаления тканей, однако имеющиеся данные о структурных изменениях печени очень ограничены, что требует дальнейших исследований в этом направлении.

метаболически ассоциированная жировая болезнь печени, неалкогольная жировая болезнь печени, сахарный диабет, гипогликемические препараты, инсулинорезистентность, лечение стеатогепатита, лекарственные препараты при стеатозе, цирроз, сердечно-сосудистые заболевания

1. Bhatt H.B, Smith R. J. Fatty liver disease in diabetes mellitus. Hepatobiliary Surg Nutr. 2015:101-8. doi: 10.3978/j.issn.2304-3881.2015.01.03.

2. Younossi Z.M, Golabi P, Paik J.M et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77:1335-1347. doi: 10.1097/HEP.0000000000000004.

3. Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022; 10:284-296. doi: 10.1016/S2213-8587(22)00003-1.

4. Sanyal A.J, Van Natta M.L, Clark J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021; 385(17):1559-1569. doi: 10.1056/NEJMoa2029349.

5. Kim Y., Chang Y., Ryu S. et al. NAFLD improves risk prediction of type 2 diabetes: with effect modification by sex and menopausal status. Hepatology. 2022; 76(6):1755-1765. doi: 10.1002/hep.32560.

6. Cusi K. Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes. Diabetes Care. 2020; 43(2):275-279. doi: 10.2337/dci19-0064.

7. Kanwal F, Shubrook J.H, Younossi Z. et al. Preparing for the NASH epidemic: a call to action. Diabetes Care. 2021; 44(9):2162-2172. doi: 10.2337/dci21-0020.

8. Gastaldelli A., Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 2019; 1(4):312-328. doi: 10.1016/j.jhepr.2019.07.002.

9. Budd J., Cusi K. Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease. Curr Diab Rep. 2020; 20(11):59. doi: 10.1007/s11892-020-01349-1.

10. Cusi K., Isaacs S., Barb D., et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022; 28(5):528-562 doi: 10.1016/j.eprac.2022.03.010.

11. ElSayed N.A, Aleppo G., Aroda V. R. et al.; American Diabetes Association. 4.Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes. Diabetes care. 2023:1; 46(9):1722. doi: 10.2337/dc23-S004.

12. Rinella M.E, Neuschwander-Tetri B.A, Siddiqui M. S. et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023; 77(5):1797-1835. doi: 10.1097/HEP.0000000000000323.

13. Lazebnik L. B., Golovanova E. V., Turkina S. V., Raikhelson K. L., Okovityy S. V., Drapkina O. M., et al. Non-alcoholic fatty liver disease in adults: Clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4-52. (In Russ.) doi: 10.31146/1682-8658-ecg-185-1-4-52.@@ Лазебник Л. Б., Голованова Е. В., Туркина С. В., Райхельсон К. Л., Оковитый С. В., Драпкина О. М. и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;1(1):4-52. doi: 10.31146/1682-8658-ecg-185-1-4-52.

14. Russian Society for the Study of the Liver. [Clinical guidelines for non-alcoholic fatty liver disease]. (2024). Moscow: 2024.144 P. (in Russ.) Available at: https://rsls.ru/files/KRNGBP2024.pdf@@ Российское общество по изучению печени. Клинические рекомендации по неалкогольной жировой болезни печени (2024). М.:2024.144с. Режим доступа https://rsls.ru/files/KRNGBP2024.pdf

15. Belfort R., Harrison S.A, Brown K. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355(22):2297-307. doi: 10.1056/NEJMoa060326.

16. Genua I., Cusi K. Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies. Diabetes Spectr. 2024; 37(1):48-58. doi: 10.2337/dsi23-0012.

17. Cusi K., Orsak B., Bril F. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016:6; 165(5):305-15. doi: 10.7326/M15-1774.

18. Huang J. F., Dai C. Y., Huang C. F. et al. First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. Hepatol Int. 2021; 15(5):1136-1147. doi: 10.1007/s12072-021-10242-2.

19. Bril F., Biernacki D. M., Kalavalapalli S. et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2019; 42(8):1481-1488. doi: 10.2337/dc19-0167.

20. Aithal G. P., Thomas J. A., Kaye P. V. et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008; 135(4):1176-84.doi: 10.1053/j.gastro.2008.06.047.

21. Sanyal A.J., Chalasani N., Kowdley K. V. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362(18):1675-85. doi: 10.1056/NEJMoa0907929.

22. Musso G., Cassader M., Paschetta E. et al. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 2017; 177(5):747. doi: 10.1001/jamainternmed.2016.9607.

23. Lian J., Fu J. Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis. Front Endocrinol. 2022; 13:840299. doi: 10.3389/fendo.2021.615409.

24. Ratziu V., Giral P., Jacqueminet S. et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT). Gastroenterology. 2008; 135(1):100-110. doi: 10.1053/j.gastro.2008.03.078.

25. Davies M. J., Aroda V. R., Collins B. S. et al. Management of hyperglycemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022; 45(11):2753-2786. doi: 10.2337/dci22-0034.

26. DeFronzo RA, Inzucchi S, Abdul-Ghani M, et al. Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019; 16:133-143. doi: 10.1177/1479164118825376.

27. Lebovitz H. E. Thiazolidinediones: the forgotten diabetes medications. Curr Diab Rep. 2019; 19(12):151. doi: 10.1007/s11892-019-1270-y.

28. Gastaldelli A., Sabatini S., Carli F. et al. PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. Liver Int. 2021; 41(11):2659-2670. doi: 10.1111/liv.15005.

29. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study: the Pioglitazone 001 Study Group. Diabetes Care. 2000;23(11):1605-1611. doi: 10.2337/diacare.23.11.1605.

30. DeFronzo R.A, Tripathy D., Schwenke D. C. et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J. Med 2011; 364(12):1104-1115. doi: 10.1056/NEJMoa1010949.

31. Kernan W.N, Viscoli C. M., Furie K. L. et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016; 374(14):1321-1331. doi: 10.1056/NEJMoa1506930.

32. Zhou Y., Huang Y., Ji X. et al. Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis. J Clin Endocrinol Metab. 2020; 105(5): dgz252. doi: 10.1210/clinem/dgz252.

33. Dormandy J. A., Charbonnel B., Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366(9493):1279-1289. doi: 10.1016/S0140-6736(05)67528-9.

34. Nesti L., Tricò D., Mengozzi A. et al. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovasc Diabetol. 2021; 20(1):109. doi: 10.1186/s12933-021-01294-7.

35. Nissen S.E, Nicholls S.J, Wolski K. et al.Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008; 299(13):1561-1573. doi: 10.1001/jama.299.13.1561.

36. Moody A. J., Molina-Wilkins M., Clarke G. D. et al. Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes. Diabetes Obes Metab. 2023; 25(2):426-434. doi: 10.1111/dom.14885.

37. Mudaliar S., Chang A.R, Henry R. R. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract. 2003; 9(5):406-416.doi: 10.4158/EP.9.5.406.

38. Jain R, Osei K, Kupfer S. et al. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy. 2006; 26(10):1388-1395. doi: 10.1592/phco.26.10.1388.

39. Pavlova V., Filipova E., Uzunova K. et al. Pioglitazone therapy and fractures: systematic review and meta-analysis. Endocr Metab Immune Disord Drug Targets. 2018; 18(5):502-507. doi: 10.2174/1871530318666180423121833.

40. Viscoli CM, Inzucchi SE, Young LH, et al. Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. J Clin Endocrinol Metab. 2017; 102(3):914-922. doi: 10.1210/jc.2016-3237.

41. Portillo-Sanchez P, Bril F, Lomonaco R, et al. Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: a 36-month clinical trial. J Diabetes. 2019; 11(3):223-231. doi: 10.1111/1753-0407.12833.

42. Lewis J.D, Habel L.A, Quesenberry C. P. et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015; 314(3):265-277. doi: 10.1001/jama.2015.7996.

43. Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017; 5(11):887-897. doi: 10.1016/S2213-8587(17)30317-0.

44. Hampp C., Pippins J. Pioglitazone and bladder cancer: FDA’s assessment. Pharmacoepidemiol Drug Saf. 2017; 26(2):117-118. doi: 10.1002/pds.4154.

45. Yilmaz Y., Yonal O., Deyneli O. et al. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg. 2012; 75(2):240-244. PMID: 22870790.

46. Iwasaki T., Yoneda M., Inamori M. et al. Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology. 2011; 58(112):2103-2105. doi: 10.5754/hge11263.

47. Ohki T, Isogawa A, Iwamoto M, et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. Scientific World Journal. 2012; 2012:496453. doi: 10.1100/2012/496453.

48. Dos Santos L. R., Duarte M. L., Peccin M. S. et al. Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis. Curr Diabetes Rev. 2021; 17(5): e101120187811. doi: 10.2174/1573399816999201110195634.

49. Abrahami D., Douros A., Yin H. et al. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. bmJ. 2018;363: k4880. doi: 10.1136/bmj.k4880.

50. Abrahami D., Douros A., Yin H. et al. Dipeptidyl pepti- dase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. bmJ. 2018;360: k872. doi: 10.1136/bmj.k872.

51. Sumida Y., Yoneda M., Tokushige K. et al. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis.International journal of molecular sciences. 2020; 21(6):1907. doi: 10.3390/ijms21061907.

52. Xu B., Li S., Kang B., Zhou J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol. 2022; 21(1):83. doi: 10.1186/s12933-022-01512-w.

53. Veelen A, Andriessen C, Op den Kamp Y. et al. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrte metabolism in prediabetic insulin resistant individuals: a randomized, double-blind crossover trial. Metabolism. 2023; 140:155396. doi: 10.1016/j.metabol.2022.155396.

54. Androutsakos T., Nasiri-Ansari N., Bakasis A. D. et al. SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection.Int J Mol Sci. 2022; 23(6):3107. doi: 10.3390/ijms23063107.

55. Latva-Rasku A., Honka M. J., Kullberg J. et al. The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients. Diabetes Care. 2019; 42(5):931-937. doi: 10.2337/dc18-1569.

56. Kahl S., Gancheva S., Straßburger K. et al. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care. 2020; 43(2):298-305. doi: 10.2337/dc19-0641.

57. Gaborit B., Ancel P., Abdullah A. E. et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc Diabetol. 2021; 20(1):57. doi: 10.1186/s12933-021-01237-2.

58. Elhini S.H, Wahsh E.A, Elberry A. A. et al. The impact of an SGLT2 inhibitor versus ursodeoxycholic acid on liver steatosis in diabetic patients. Pharmaceuticals (Basel). 2022; 15(12):1516. doi: 10.3390/ph15121516.

59. Cusi K, Bril F, Barb D, et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019; 21(4):812-821. doi: 10.1111/dom.13584.

60. Bolinder J., Ljunggren Ö., Kullberg J. et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97(3):1020-31. doi: 10.1210/jc.2011-2260.

61. Eriksson J., Lundkvist P., Jansson P. et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018; 61(9):1923-1934. doi: 10.1007/s00125-018-4675-2.

62. Phrueksotsai S, Pinyopornpanish K, Euathrongchit J. et al. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2021; 36(10):2952-2959. doi: 10.1111/jgh.15580.

63. Taheri H., Malek M., Ismail-Beigi F. et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Adv Ther. 2020; 37(11):4697-4708. doi: 10.1007/s12325-020-01498-5.

64. Chehrehgosha H., Sohrabi M.R, Ismail-Beigi F. et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Ther. 2021; 12(3):843-861. doi: 10.1007/s13300-021-01011-3.

65. Jang H, Kim Y, Lee DH, et al. Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease. JAMA Intern Med. 2024; 184(4):375-383. doi: 10.1001/jamainternmed.2023.8029.

66. Iwamoto Y., Kimura T., Dan K. et al. Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice. Diabetes Obes Metab. 2024; 26(6):2339-2348. doi: 10.1111/dom.15548.

67. Drzewoski J., Hanefeld M. The Current and Potential Therapeutic Use of Metformin-The Good Old Drug. Pharmaceuticals (Basel). 2021; 14(2):122. doi: 10.3390/ph14020122.

68. Duell P., Welty F., Miller M. et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022; 42(6): e168-e185. doi: 1161/ATV.0000000000000153.